The Evolving Landscape of Chronic Lymphocytic Leukemia: Selecting and Managing Targeted Therapy - a podcast by ReachMD

from 2021-07-16T00:00

:: ::

CME credits: 0.50

Valid until: 16-07-2022

Claim your CME credit at https://reachmd.com/programs/cme/evolving-landscape-chronic-lymphocytic-leukemia-selecting-and-managing-targeted-therapy/12643/



Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy associated with different cytogenetic, immunophenotypic, and morphological profiles. This diversity has resulted in varying clinical courses and responses to therapy and underscores the importance of individualizing therapy. The availability of targeted therapies has dramatically transformed the CLL therapeutic landscape, providing options for personalized treatments within both the newly diagnosed and relapsed/refractory (R/R) settings.

In this educational activity, faculty members review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or R/R CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD